- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Gaithersburg Today
By the People, for the People
Analyzing Applied DNA Sciences and 20/20 Biolabs
Two small-cap biotech firms compete in the diagnostics and drug development markets
Mar. 28, 2026 at 12:18am
Got story updates? Submit your updates here. ›
20/20 Biolabs (NASDAQ:AIDX) and Applied DNA Sciences (NASDAQ:BNBX) are both small-cap biotech companies that provide a range of diagnostic and drug development services. This analysis compares the two firms across key metrics like revenue, earnings, institutional ownership, and analyst recommendations to determine which is the superior business.
Why it matters
The biotech industry is highly competitive, with small-cap firms constantly vying for market share, investment, and strategic partnerships. Understanding the relative strengths and weaknesses of 20/20 Biolabs and Applied DNA Sciences can help investors, analysts, and industry observers assess the long-term growth potential of these two emerging players.
The details
20/20 Biolabs and Applied DNA Sciences both operate in the diagnostics and drug development space, but with some key differences. 20/20 Biolabs focuses on AI-powered blood tests for early cancer and disease detection, while Applied DNA Sciences provides DNA-based supply chain security, authentication, and COVID-19 testing solutions. 20/20 Biolabs has higher revenue and earnings than Applied DNA Sciences, and also has stronger institutional ownership at 22.2% versus 0.0% for Applied DNA. However, Applied DNA has a more diversified revenue mix, with COVID-19 testing accounting for 18% of sales in 2023.
- 20/20 Biolabs expects to launch its OneTest for Longevity product in the first half of 2026.
- Applied DNA Sciences was formerly known as Datalink Systems, Inc. and changed its name in 2002.
The players
20/20 Biolabs
A biotech company that develops AI-powered blood tests for early cancer and disease detection, operating a CLIA-licensed laboratory in Gaithersburg, Maryland.
Applied DNA Sciences
A biotech firm that provides DNA-based technology solutions for supply chain security, authentication, and COVID-19 testing, headquartered in Stony Brook, New York.
The takeaway
The competition between 20/20 Biolabs and Applied DNA Sciences highlights the dynamic nature of the biotech industry, where small-cap firms must constantly innovate and differentiate to gain a competitive edge. Investors will be closely watching the commercial performance and strategic moves of these two companies as they vie for market share and investment capital.
